Telmisartan for portal hypertension in patients with compensated advanced chronic liver disease: A randomized placebo-controlled, double-blind trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513351-33-00

Acronym

TECA

Enrollment

100

Registered

2025-01-13

Start date

2025-03-21

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

compensated advanced chronic liver disease, portal hypertension

Brief summary

The primary endpoint is defined as the difference between HVPG at W12 and baseline.

Detailed description

HVPG response after 12 weeks of treatment is defined as an HVPG decrease ≥10%; i.e., HVPG responders)., Change in liver stiffness measurement (in kPa) between W12 and baseline, Change in spleen stiffness measurement (in kPa) between W12 and baseline)

Interventions

DRUGPlacebo consists of gelatin capsules filled with maltodextrin

DRUGTelmicard 40 mg-Tabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is defined as the difference between HVPG at W12 and baseline.	—

Secondary

Measure	Time frame
HVPG response after 12 weeks of treatment is defined as an HVPG decrease ≥10%; i.e., HVPG responders)., Change in liver stiffness measurement (in kPa) between W12 and baseline, Change in spleen stiffness measurement (in kPa) between W12 and baseline)	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026